Live prices from 7 SA suppliers, from R490.00, compared side by side so you never overpay.
Copy the code — you'll paste it at checkout.
with our exclusive code
You're about to visit an external supplier
with our exclusive code
By clicking "Continue", you acknowledge that you understand and accept the above. Read our full disclosure.
Compare 4 prices for VIP. Cheapest: R700.00. Average: R1,139.71.
| Compare | Visit | |||||||
|---|---|---|---|---|---|---|---|---|
Crono Pharm
Best
VIP |
R700.00 | R70.00/mg | In Stock | R150.00 |
Lab Tested
|
— | ||
|
VIP 10mg |
R900.00 | R90.00/mg | In Stock | R150.00 |
Lab Tested
|
— | ||
|
VIP 10mg |
R1,350.00 | R135.00/mg | In Stock | R170.00 |
—
|
— | ||
|
VIP 10mg |
R1,608.85 | R160.89/mg | In Stock | R250.00 |
Lab Tested
|
— |
More ways to compare VIP
Different views of the same live SA pricing, tuned for how you like to shop.
Compare another peptide
All purchases are made directly from third-party suppliers; your relationship is solely with them. We accept no liability for the quality, purity, or legality of any products listed.
We may earn a commission when you click through to a supplier and make a purchase. This does not affect pricing information displayed.
By using this site you accept responsibility for ensuring purchases comply with applicable laws in your jurisdiction. Read our full disclosure.
Vasoactive Intestinal Peptide | Neuropeptide
Vasoactive Intestinal Peptide (VIP) is a 28-amino acid neuropeptide belonging to the glucagon/secretin superfamily. It is produced in many tissues including the gut, pancreas, and brain. VIP has potent vasodilatory, anti-inflammatory, and immunomodulatory effects. It binds to VPAC1 and VPAC2 receptors, triggering cAMP-mediated signaling cascades. Research shows therapeutic potential for pulmonary hypertension, diabetes, neurological disorders, and autoimmune conditions.
VIP binds to VPAC1 and VPAC2 G protein-coupled receptors, activating adenylyl cyclase and increasing intracellular cAMP and PKA activity. This triggers phosphorylation of CREB and other transcription factors. VIP causes vasodilation through NO-dependent and independent mechanisms, stimulates intestinal secretion, relaxes smooth muscle, inhibits gastric acid secretion, and has positive inotropic/chronotropic cardiac effects.
HSDAVFTDNYTRLRKQMAVKKYLNSILN?
Histidine
Position 1
Serine
Position 2
Aspartic Acid
Position 3
Alanine
Position 4
Valine
Position 5
Phenylalanine
Position 6
Threonine
Position 7
Aspartic Acid
Position 8
Asparagine
Position 9
Tyrosine
Position 10
Threonine
Position 11
Arginine
Position 12
Leucine
Position 13
Arginine
Position 14
Lysine
Position 15
Glutamine
Position 16
Methionine
Position 17
Alanine
Position 18
Valine
Position 19
Lysine
Position 20
Lysine
Position 21
Tyrosine
Position 22
Leucine
Position 23
Asparagine
Position 24
Serine
Position 25
Isoleucine
Position 26
Leucine
Position 27
Asparagine
Position 28
NH2
Position 29
VIP inhalation shows striking efficacy with increased mixed venous oxygen saturation and exercise capacity.
Dilates peripheral blood vessels through NO-dependent mechanisms above 100 pmol doses.
Coronary vasodilation with positive inotropic and chronotropic effects on the heart.
Promising therapeutic target for Alzheimer's, Parkinson's, and other neurological disorders.
Potential therapeutic target being researched for ASD.
Produced in suprachiasmatic nuclei; involved in circadian regulation.
Promotes insulin secretion in glucose-dependent manner via VPAC2; low hypoglycemia risk.
Potent anti-inflammatory effects useful in IBD and autoimmune conditions.
Therapeutic potential for pulmonary and systemic sarcoidosis.
VIP has a very short half-life of approximately 2 minutes in blood, requiring careful dosing strategies. Subcutaneous or intravenous administration. Rapid degradation limits bioavailability; analogs like stearyl-Nle17-VIP (SNV) are 100-fold more potent.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| General use | 50-100 mcg | 1-2x daily | SubQ or IV |
| Research protocols | 100-200 mcg | As directed | SubQ or IV |
Inhalation route researched for pulmonary hypertension. Safety demonstrated in healthy and asthmatic subjects at 100 μM concentrations.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Pulmonary hypertension | 100-200 mcg/day | Daily (inhaled) | Inhalation |
No known negative interactions; different mechanisms.
Both have immunomodulatory effects; may complement each other.
Both have anti-inflammatory properties.
Rapid vasodilation and hemodynamic effects
Anti-inflammatory signaling activated
Cumulative effects on inflammation and immune balance
Sustained benefits with regular administration
Journal of Clinical Investigation
VIP inhalation showed striking efficacy with increased mixed venous oxygen saturation and exercise capacity.
Frontiers in Endocrinology
VIP promotes glucose-dependent insulin secretion via VPAC2, reducing hypoglycemia risk.
CNS Neuroscience & Therapeutics
VIP and receptors are promising therapeutic targets for AD, PD, and autism spectrum disorders.
Pharmacology & Therapeutics
Comprehensive review of VIP receptor signaling and therapeutic applications.
Plain-English guides and study summaries from published literature.
Guides
8 min
VIP is a widely studied neuropeptide involved in vascular tone, airway biology, immune signalling and circadian regulation. This guide explains what the research can and cannot support.
Read article
Guides
6 min
VIP is a 28-amino acid neuropeptide studied for vascular tone, immune signalling, respiratory function and neurological pathways. This guide explains the research without overstating its use.
Read articleBe the first to know when prices drop on your favourite peptides
No spam. Unsubscribe anytime. We respect your privacy.